REGN Income Statement
Regeneron Pharmaceuticals Inc - Revenue, Expenses & Profit Analysis
Stock Price
$781.67
Market Cap
$82.64B
P/E Ratio
18.8
EPS (TTM)
$41.51
Most Recent Quarter
Period: FY(2025-12-31)
Revenue
Total sales from operations
$14.34B
+1.0% YoY
Operating Income
Gross Profit - Operating Expenses
$3.58B
Margin: 0.2%
Net Income
Bottom line profit
$4.50B
Margin: 0.3%
Earnings Per Share (Diluted)
Net income per share
$41.48
Profitability Metrics
Gross Margin
44.6%
Operating Margin
0.2%
Net Margin
0.3%
Return on Equity
0.1%
Historical Income Statements
| Period | Revenue | Gross Profit | Operating Income | Net Income | EPS |
|---|---|---|---|---|---|
| FY | $14.34B | - | $3.58B | $4.50B | $41.48 |
| 2024-12-31 | $14.20B | - | - | $4.41B | $38.34 |
| FY | $14.20B | - | $3.99B | $4.41B | $38.34 |
| 2023-12-31 | $13.12B | - | - | $3.95B | $34.77 |
| FY | $13.12B | - | $4.05B | $3.95B | $34.77 |
View Complete Financial Analysis
Full income statements, balance sheets, cash flows, and AI-powered insights
Open Full AnalysisFrequently Asked Questions
What is REGN's revenue?
REGN's most recent quarterly revenue was $14.34B, representing a growth of 1.0% year-over-year.
Is REGN profitable?
REGN reported a profit of $4.50B in the most recent quarter. The net profit margin is 0.3%.
What is REGN's operating income?
REGN's operating income was $3.58B in the most recent quarter. The operating margin is 0.2%.
What is REGN's earnings per share (EPS)?
REGN reported diluted earnings per share of $41.48 in the most recent quarter.
What is REGN's gross profit margin?
REGN has a gross profit margin of 44.6%, indicating the profitability of core operations before operating expenses.